Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 7/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17916795 | 1.00 | ALOX15 (0.41) | ALOX15ALOX12ESR2MEN1MAPT | |
| Me-344 SCHEMBL30362759 | 0.96 | ESR2 (0.36) | ALOX15ALOX12ESR2ESR1PTGS1 | |
| Me-344 SCHEMBL10073998 | 0.96 | ESR2 (0.36) | ALOX15ALOX12ESR2ESR1PTGS1 | |
| Me-344 SCHEMBL15312098 | 0.96 | ESR2 (0.36) | ALOX15ALOX12ESR2ESR1PTGS1 | |
| Me-344 SCHEMBL30276333 | 0.96 | ESR2 (0.36) | ALOX15ALOX12ESR2ESR1PTGS1 | |
| Me-344 SCHEMBL29370582 | 0.96 | ESR2 (0.36) | ALOX15ALOX12ESR2ESR1PTGS1 | |
| Me-344 SCHEMBL2713213 | 0.96 | ESR2 (0.36) | ALOX15ALOX12ESR2ESR1PTGS1 | |
| Me-344 SCHEMBL17965959 | 0.96 | ESR2 (0.36) | ALOX15ALOX12ESR2ESR1PTGS1 | |
| SCHEMBL10042959 | 0.89 | ALOX15 (0.44) | ALOX15ALOX12ALDH1A1ACHEPTGS1 | |
| SCHEMBL301907 | 0.89 | ALOX15 (0.44) | ALOX15ALOX12ESR2MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372287-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | Aardvark Therapeutics, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-20230233519-A1 | COMBINATION THERAPIES | Aardvark Therapeutics, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-20230145478-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | MEI PHARMA, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20170246142-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | Aardvark Therapeutics, Inc. | 2017-08-31 | — | — | US | disclosed |
| US-9663484-B2 | Isoflavonoid compounds and methods for the treatment of cancer | MEI PHARMA, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20140234295-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | MARSHALL EDWARDS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145478-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | BAX, CASP3, API5 | ALOX15 1218/4885ALOX12 1002/4885ESR2 22/4885 |
| US-20230233519-A1 | COMBINATION THERAPIES | BCL2, BAK1, BCL2L2 | ALOX15 3836/4885ALOX12 3313/4885ESR2 2187/4885 |
| US-20140234295-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | BAX, CASP3, API5 | ALOX15 1218/4885ALOX12 1002/4885ESR2 22/4885 |
| US-20230372287-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | BAX, CASP3, API5 | ALOX15 1218/4885ALOX12 1002/4885ESR2 22/4885 |
| US-20170246142-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | BAX, CASP3, API5 | ALOX15 1218/4885ALOX12 1002/4885ESR2 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.